JP2020528910A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528910A5
JP2020528910A5 JP2020504133A JP2020504133A JP2020528910A5 JP 2020528910 A5 JP2020528910 A5 JP 2020528910A5 JP 2020504133 A JP2020504133 A JP 2020504133A JP 2020504133 A JP2020504133 A JP 2020504133A JP 2020528910 A5 JP2020528910 A5 JP 2020528910A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
aspects
composition according
tablets
series
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043867 external-priority patent/WO2019023439A1/en
Publication of JP2020528910A publication Critical patent/JP2020528910A/ja
Publication of JP2020528910A5 publication Critical patent/JP2020528910A5/ja
Pending legal-status Critical Current

Links

JP2020504133A 2017-07-28 2018-07-26 オリゴヌクレオチド化合物の調製方法 Pending JP2020528910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538504P 2017-07-28 2017-07-28
US62/538,504 2017-07-28
PCT/US2018/043867 WO2019023439A1 (en) 2017-07-28 2018-07-26 PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDE COMPOUNDS

Publications (2)

Publication Number Publication Date
JP2020528910A JP2020528910A (ja) 2020-10-01
JP2020528910A5 true JP2020528910A5 (cg-RX-API-DMAC7.html) 2021-09-09

Family

ID=65041406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504133A Pending JP2020528910A (ja) 2017-07-28 2018-07-26 オリゴヌクレオチド化合物の調製方法

Country Status (6)

Country Link
US (1) US20200392491A1 (cg-RX-API-DMAC7.html)
EP (1) EP3658155A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020528910A (cg-RX-API-DMAC7.html)
KR (1) KR20200042902A (cg-RX-API-DMAC7.html)
CN (1) CN111148519A (cg-RX-API-DMAC7.html)
WO (1) WO2019023439A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
JP7503072B2 (ja) * 2019-02-26 2024-06-19 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドの製剤化方法
CN114051499A (zh) * 2019-07-09 2022-02-15 豪夫迈·罗氏有限公司 用于寡核苷酸的脱保护的方法
CN110468171B (zh) * 2019-09-20 2021-10-29 凯莱英医药集团(天津)股份有限公司 核酸的合成方法
KR20220156843A (ko) 2020-02-21 2022-11-28 바이오젠 엠에이 인코포레이티드 한외여과 / 정용여과를 사용한 올리고뉴클레오티드 조성물의 제조 방법
WO2024138152A1 (en) * 2022-12-23 2024-06-27 Asahi Kasei Bioprocess America, Inc. System for performing cleavage, deprotection, ultrafiltration, and diafiltration operations
CN117143165B (zh) * 2023-08-30 2026-02-03 上海奥锐特生物科技有限公司 一种寡核苷酸的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050789A2 (en) * 2005-10-25 2007-05-03 Nëdken Corporation Glycosyl-oligonucleotide conjugates and methods
DK2951191T3 (en) * 2013-01-31 2019-01-14 Ionis Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US20170247695A1 (en) * 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Similar Documents

Publication Publication Date Title
JP7789856B2 (ja) 活性剤の脂質ナノ粒子送達のための脂質
CN110944675B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN113150041B (zh) 一种硫代寡核苷酸的制备方法
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2022527105A5 (cg-RX-API-DMAC7.html)
JP2023515218A (ja) Pd-l1を標的とするための方法及び組成物
KR20190015311A (ko) 올리고머의 제조 방법
CN112876534A (zh) 肝靶向化合物及缀合物
JP2020528910A (ja) オリゴヌクレオチド化合物の調製方法
EP3286203B1 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
TW202140789A (zh) 靶向pd—l1之方法及組合物
TW201805002A (zh) 磷醯二胺嗎啉代寡聚物醫藥組合物
JP2023543898A5 (cg-RX-API-DMAC7.html)
CN112007040B (zh) 用于治疗乙型病毒性肝炎的联合用药物
Grajkowski et al. An expedient process for reducing the formation of process-related impurities during solid-phase synthesis of potential nucleic acid-based drugs
Zhu et al. Preparation and physical properties of conjugates of oligodeoxynucleotides with poly (δ) ornithine peptides
JP2003204793A (ja) ウイルス性疾患の予防または治療剤
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
Sato et al. New Molecular Technologies for Oligonucleotide Therapeutics-1: Properties and Synthesis of Boranophosphate DNAs
TW202610667A (zh) 用於寡核苷酸之口服投予的新穎調配物
EP3805242A1 (en) Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma
JPH02237930A (ja) 新規オリゴデオキシヌクレオチドおよび該オリゴデオキシヌクレオチドを有効成分とする制癌剤
EA052594B1 (ru) Конъюгат нуклеиновой кислоты и лиганда, способ его получения и его применения
HK40048836A (en) Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma
HK40019791B (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use